|Bid||4.55 x 1000|
|Ask||5.20 x 200|
|Day's Range||4.83 - 5.02|
|52 Week Range||3.15 - 9.49|
|PE Ratio (TTM)||-10.45|
|Earnings Date||Nov 1, 2017 - Nov 6, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||7.13|
Q2 2017 Achillion Pharmaceuticals Inc Earnings Call
Research Desk Line-up: Cambrex Post Earnings Coverage LONDON, UK / ACCESSWIRE / August 11, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Achillion ...
Thursday's downgrade is in part based on a lack of confidence in Achillion's CH-4471 to compete with Alexion Pharmaceuticals' Soliris treatment.